FSD1L

Across TCGA pan-cancer cohorts, FSD1L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FSD1L data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FSD1L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FSD1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where FSD1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.565	0.283	.012	19	view →
LUAD	OS	Median	III,IV	0.232	0.672	.005	15	view →
GBM	DFS	Tertile	All	0.901	0.574	.001	14	view →
CCRCC	DFS	Median	II,III,IV	0.852	0.469	.011	10	view →
UCEC	DFS	Tertile	All	0.974	0.850	.049	4	view →
HNSC	DFS	Tertile	All	0.696	1.000	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FSD1L–PDAC (OS)

Open the PDAC breakdown →